HDC/IL-2 is approved for maintenance of first CR in patients within the EU and was recently shown to reduce relapse risk in younger adults (<60 years old) with favorable outcome of previous chemotherapy and in AML of normal karyotype. Here, IL2 is linked to acute myeloid leukemia.